
Last updated: 2026-10-17 18:49:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Jyong Biotech Ltd. (MENS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.82, with a market capitalisation of $146.98M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.43 to $63.00. This page covers its latest market performance, valuation, price trends and company information.
$146.98M | |
$1.97 | |
$67.00 | |
$1.43 | |
$1.98 | |
40.47K | |
45.51K | |
-- | |
$63.00 | |
$1.43 | |
-- | |
-- |
Jyong Biotech Ltd. (MENS) last closed at $1.98 as of 2026-10-16 23:31:00, unchanged from the previous close of $1.98.
During the latest regular trading session, MENS traded between $1.43 and $67.00, with a volume of 40.47K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Jyong Biotech Ltd. (MENS) moved from $2.10 to $1.82, representing a decline of 13.33% ($0.28).
The stock traded between $1.78 and $2.18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 47.97 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.6%
MENS is currently trading at $1.82, placing it 0.6% of the way from its 52-week low of $1.43 to its 52-week high of $63.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
| Employees | 27 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jyong Biotech Ltd. (MENS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.